Announcements
- Boehringer Ingelheim and OSE Immunotherapeutics advance clinical development of first-in-class SIRP cancer immunology treatment BI 770371
- OSE Immunotherapeutics et Boehringer Ingelheim poursuivent l’avancée du développement clinique du traitement first-in-class SIRPα BI 770371 en immunologie du cancer
- Informations relatives au nombre total de droits de vote et d’actions composant le capital
- OSE Immunotherapeutics Announces Publication of Preclinical Efficacy Results with Lusvertikimab in Acute Lymphoblastic Leukemia in the Journal ‘Blood’
- OSE Immunotherapeutics annonce la publication de résultats précliniques d’efficacité de Lusvertikimab dans la Leucémie Aiguë Lymphoblastique dans le journal ‘Blood’
- OSE Immunotherapeutics Announces Commercial and Revenue Sharing Agreement in the Field of CAR T-cell Therapies
- OSE Immunotherapeutics annonce un accord commercial et de partage de revenus dans le domaine des thérapies par cellules CAR-T
- OSE Immunotherapeutics Presents Preclinical Data on mRNA Therapeutic Platform for the Treatment of Inflammatory and Autoimmune Disorders at the FOCIS Annual Meeting, San Francisco (June 18 – 21)
- OSE Immunotherapeutics présente des données précliniques sur sa plateforme ARNm thérapeutique dans le traitement des maladies auto-immunes et inflammatoires au congrès annuel FOCIS, San Francisco (18 – 21 juin)
- OSE Immunotherapeutics Reports on its 2024 General Shareholders’ Meeting and the Evolution of the Board of Directors Ready to Drive the Strategic Company’s Growth
More ▼
Key statistics
On Friday, OSE Immunotherapeutics SA (6OP:DEU) closed at 6.51, -24.21% below its 52-week high of 8.59, set on May 22, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 6.42 |
---|---|
High | 7.06 |
Low | 6.39 |
Bid | 6.49 |
Offer | 6.55 |
Previous close | 6.52 |
Average volume | 482.60 |
---|---|
Shares outstanding | 21.82m |
Free float | 15.96m |
P/E (TTM) | -- |
Market cap | 142.03m EUR |
EPS (TTM) | -1.18 EUR |
Data delayed at least 15 minutes, as of Jul 05 2024.
More ▼